Ozmosi | PRO-087 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

PRO-087

Alternative Names: pro-087, pro087, pro 087
Clinical Status: Inactive
Latest Update: 2026-01-13
Latest Update Note: Clinical Trial Update

Product Description

For Dry Eye Syndrome

Mechanisms of Action: Type 2 Collagen Stimulant

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company Founding Year: 1942
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Keratoconjunctivitis Sicca|Dry Eye Syndromes

Phase 1: Keratoconjunctivitis Sicca|Environmental Hypersensitivity|Dry Eye Syndromes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03524157

PRO-087/I

P1

Completed

Environmental Hypersensitivity|Dry Eye Syndromes|Keratoconjunctivitis Sicca

2018-02-12

2019-03-22

Treatments

NCT04702776

PRO-087

P4

Completed

Keratoconjunctivitis Sicca|Dry Eye Syndromes

2023-05-15

2026-01-14

NCT03223909

087LATAMFIV

P4

Completed

Keratoconjunctivitis Sicca|Dry Eye Syndromes

2018-10-16

2019-11-01

Recent News Events

Date

Type

Title